|From: stormcat (Rep: 464)||Date: 12/20/2017 17:08|
|Forum: AEterna Zentaris - Msg #2635||Thread #673975506 (Rec: 0) |
Aeterna Zentaris Announces FDA Approval of Macrilen ™ (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency
2017-12-20 17:00 ET - News Release
CHARLESTON, S.C., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS), a specialty biopharmaceutical company engaged in developing and commercializing pharmaceutical therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Macrilen™ (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency (AGHD). The Company estimates that approximately 60,000 tests for suspected AGHD are being conducted each year across the United States, Canada and Europe
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.